PTC Therapeutics

PTC Therapeutics said on Wednesday its experimental Huntington’s disease drug lowered mutated protein levels that cause the neurological disease, citing interim data from a mid-stage study.

x-ray, hand

Belgium-based BioSenic is suspending the development of ALLOB, an investigational allogeneic cell therapy derived from mesenchymal stem cells, which was being assessed as a treatment for tibial fractures, the company announced Monday.

Aldeyra Therapeutics said on Thursday its treatment for a common allergic eye disease met the main goal of a late-stage study, paving the way for it to become an alternative to over-the-counter eye drops.

Data from the Phase III REVISIT and ASSEMBLE studies showed that Pfizer’s investigational antibiotic combination aztreonam-avibactam could safely cure infections caused by Gram-negative bacteria, the company announced Thursday.

BioNTech

BioNTech said on Friday that a new cancer immunotherapy candidate that it is working on with U.S. partner OncoC4 Inc. was shown to shrink tumors in close to 30% of participants in a mid-stage lung cancer trial.

FDA

The FDA has placed a clinical hold on PepGen‘s Phase I trial of its neuromuscular candidate, which had been planned for the first half of the year. The Boston biopharma’s stock dropped around 18% post-market Tuesday after the announcement.

pills

Top-line results from a Phase IIa study showed that Glyscend Therapeutics’ lead candidate GLY-200 demonstrated promising safety and efficacy in patients with Type 2 diabetes, the company announced Wednesday.

FDA

Akebia Therapeutics scored a long-awaited win Tuesday when it announced the FDA has granted a path forward for vadadustat in anemia associated with chronic kidney disease in dialysis-dependent patients, which will not require the company to submit new data. 

Pfizer

U.S. drugmaker Pfizer Inc. said on Tuesday late-stage study data for its experimental hemophilia therapy showed superiority to the current standard of care treatment in reducing bleeding rates in patients.

Novo Nordisk logo headquarters

Novo Nordisk expects the oral version of its semaglutide drug to treat obesity to have similar efficacy as its Wegovy injection, with data from a late-stage clinical trial due before the end of June, a senior executive said on Thursday.